Formycon and its licensee Bioeq today announced positive interim results for a phase 3 clinical trial of FYB201, a proposed ranibizumab biosimilar referencing Lucentis, which is an anti–vascular endothelial growth factor therapy approved to treat patients with neovascular age-related macular degeneration.
Formycon and its licensee Bioeq today announced positive interim results for a phase 3 clinical trial of FYB201, a proposed ranibizumab biosimilar referencing Lucentis, which is an anti-vascular endothelial growth factor therapy approved to treat patients with neovascular age-related macular degeneration (nAMD).
According to Formycon, the COLUMBUS-AMD trial, which compared the efficacy of FYB201 of the reference ranibizumab in patients with nAMD, reached its primary efficacy endpoint, measuring the change in best corrected visual acuity after 8 weeks. The confidence interval, says the drug maker, lies within the pre-specified equivalence margin, and the study has not raised any new concerns about safety or immunogenicity.
The final patient in the trial, in which patients are treated for a total of 48 weeks, is expected to complete treatment in the second quarter of 2018. Data from the study will be included in applications for marketing approval in both the United States and Europe.
Thiemo Schreiber, PhD, of Bioeq, said in a statement, “Our aim is the approval and launch of FYB201 as the first biosimilar to Lucentis in the [United States] in 2020 and in the countries of the European Economic Area in 2022. We thus want to offer a larger number of patients more affordable access to this important and highly effective treatment.”
Other companies developing ranibizumab biosimilars include Samsung Bioepis, which began a phase 3 trial of its proposed product, SB11, in 2017. Samsung Bioepis projects that it will have collected its primary outcome data by April of 2019. Additionally, Pfenex, which reassumed rights to PF582 from Pfizer in 2016, has indicated that it may be considering resuming work on its biosimilar candidate after having halted development due to costs and a long development timeline. In April 2018, Pfenex indicated that it was interested in working with a strategic development partner to advance its program.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.